Elimox Consortium endocrine/metabolic news

The two-year Elimox consortium received a €2.2 million ($3 million) grant from the EU's Framework Programme 7 (FP7) to develop a treatment for primary hyperoxaluria. The consortium, led by OxThera AB (Uppsala, Sweden), will develop a bacterial pharmaceutical product using Oxalobacter formigenes, a bacterium that has been shown to actively promote enteric elimination of oxalate in animal models. The partners will manufacture an anaerobic bacterial product for administration in the gut, develop analytical tools to verify quality, delivery and activity of the bacterial product, and conduct clinical development of the product. ...